Arbutin alleviates fatty liver by inhibiting ferroptosis via FTO/SLC7A11 pathway

Tianyu Jiang,Yao Xiao,Jinfeng Zhou,Zupeng Luo,Lin Yu,Qichao Liao,Siqi Liu,Xinyi Qi,Hao Zhang,Menglong Hou,WeiWei Miao,Batbold Batsaikhan,Turtushikh Damba,Yunxiao Liang,Yixing Li,Lei Zhou
DOI: https://doi.org/10.1016/j.redox.2023.102963
IF: 11.4
2023-11-18
Redox Biology
Abstract:Non-alcoholic fatty liver disease (NAFLD) is a potentially serious disease that affects 30 % of the global population and poses a significant risk to human health. However, to date, no safe, effective and appropriate treatment modalities are available. In recent years, ferroptosis has emerged as a significant mode of cell death and has been found to play a key regulatory role in the development of NAFLD. In this study, we found that arbutin (ARB), a natural antioxidant derived from Arctostaphylos uva-ursi (L.) , inhibits the onset of ferroptosis and ameliorates high-fat diet-induced NAFLD in vivo and in vitro . Using reverse docking, we identified the demethylase fat mass and obesity-related protein (FTO) as a potential target of ARB. Subsequent mechanistic studies revealed that ARB plays a role in controlling methylation of the SLC7A11 gene through inhibition of FTO. In addition, we demonstrated that SLC7A11 could alleviate the development of NAFLD in vivo and in vitro . Our findings identify the FTO/SLC7A11 axis as a potential therapeutic target for the treatment of NAFLD. Specifically, we show that ARB alleviates NAFLD by acting on the FTO/SLC7A11 pathway to inhibit ferroptosis.
biochemistry & molecular biology
What problem does this paper attempt to address?